The invention relates to compounds of the general formula (I): ##STR00001## wherein Ar is optionally substituted aryl or heteroaryl; A is (i) --O--, --S--, --SO.sub.2--, --NH--, (ii) a C.sub.1-4-alkyl- or C.sub.1-6-acyl-substituted nitrogen atom or (iii) a C.sub.1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is --C(R.sub.4)(R.sub.5)--, --OC(R.sub.4)(R.sub.5)--, --N(R.sub.6)C(R.sub.4)(R.sub.5)--, --N(R.sub.6)--, --O--, --S-- or --SO.sub.2--; R is optionally substituted C.sub.3-8-cycloalkyl, aryl or heteroaryl; R.sub.1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group --[C(R.sub.4)(R.sub.5)].sub.xN(R.sub.2a)(R.sub.3a)]; R.sub.2a, R.sub.3a, R.sub.4, R.sub.5, R.sub.6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof. The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).
This application is a continuation of U.S. application Ser. No. 10/269,670, filed on Oct. 11, 2002, which is a divisional of U.S. application Ser. No. 09/589,282, filed Jun. 8, 2000 (now U.S. Pat. No. 6,465,467, issued Oct. 15, 2002), which is a continuation-in-part of U.S. application Ser. No. 09/573,348, filed on May 19, 2000, abandoned, which claims the benefit of U.S. Provisional application Ser. No. 60/137,527, filed on Jun. 3, 1999, and of Swedish Application No. 9901884-8, filed on May 21, 1999, the entire contents each of which are incorporated by reference in their entirety.
A compound of formula (I): ##STR00001## for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NR.sup.X or CR.sup.XR.sup.Y; if X=NR.sup.X then n is 1 or 2 and if X=CR.sup.XR.sup.Y then n is 1; R.sup.X is selected from the group consisting of H, optionally substituted C.sub.1-20 alkyl, C.sub.5-20 aryl, C.sub.3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R.sup.Y is selected from H, hydroxy, amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1 and R.sup.C2 are independently selected from the group consisting of hydrogen and C.sub.1-4 alkyl, or when X is CR.sup.XR.sup.Y, R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R.sup.1 is selected from H and halo; and Het is selected from: ##STR00002## where Y.sup.1 is selected from CH and N, Y.sup.2 is selected from CH and N, Y.sup.3 is selected from CH, CF and N, where only one or two of Y.sup.1, Y.sup.2 and Y.sup.3 can be N; and ##STR00003## where Q is O or S.
